WebMay 14, 2024 · Grade 3-4 toxicities reported more frequently for vinorelbine plus cisplatin than for pemetrexed plus cisplatin were febrile neutropenia (11.6% v 0.3%, … WebGemcitabine/CISplatin Gemcitabine CISplatin Increases platinum-DNA adducts and lessens toxicity 100, 101 Mesothelioma Regimens CISplatin/Gemcitabine Gemcitabine CISplatin Less toxic 102, 103 PEMEtrexed/CARBOplat in PEMEtrexed CARBOplatin N/A …
Osimertinib or Platinum–Pemetrexed in EGFR …
WebApproximately one third of patients with non–small-cell lung cancer (NSCLC) have stage III, locally advanced disease at diagnosis. 1 The standard of care for patients with a good performance status... WebOct 18, 2011 · Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) - Full Text View - ClinicalTrials.gov … csis slcc
First-Line Atezolizumab plus Chemotherapy in …
Inhibitors of programmed death 1 (PD-1) and its ligand PD-L1 are effective therapies for metastatic nonsmall-cell lung cancer (NSCLC) lacking sensitizing EGFR or ALK mutations. Pembrolizumab (Keytruda, Merck), nivolumab (Opdivo, Bristol-Myers Squibb), and atezolizumab (Tecentriq, Genentech) are approved as … See more Patients who were at least 18 years of age were eligible for enrollment if they had pathologically confirmed metastatic nonsquamous … See more The trial was designed by a panel of academic advisors and employees of Merck (in Kenilworth, New Jersey), the trial sponsor. An … See more In this double-blind trial, patients were randomly assigned, in a 2:1 ratio, to receive either 200 mg of pembrolizumab or saline placebo, both administered intravenously every 3 weeks for up to 35 cycles. … See more Efficacy was assessed in the intention-to-treat population, which included all the patients who had undergone randomization. Safety was assessed in the as-treated … See more WebMar 29, 2015 · Cisplatin-based regimens are associated with enhanced efficacy and toxicity as compared with carboplatin-based therapy 32,33; yet in CALGB protocol 9633, 27 33 percent of patients required dose... eagle hill school hardwick